Quality of life, mucositis, and xerostomia from radiotherapy for head and neck cancers: A report from the NCIC CTG HN2 randomized trial of an antimicrobial lozenge to prevent mucositis

Head and Neck

Volumn 27, Issue 5, 2005, Pages 421-428

  Duncan, Graeme G ^a   Epstein, Joel B ^a   Tu, Dongsheng ^b   El Sayed, Samy ^c   Bezjak, Andrea ^d   Ottaway, Jon ^b   Pater, Joe ^b  

^a BRITISH COLUMBIA CANCER AGENCY   (Canada)

^b QUEEN S UNIVERSITY   (Canada)

^c OTTAWA REGIONAL CANCER CENTRE   (Canada)

^d PRINCESS MARGARET HOSPITAL   (Canada)

Author keywords

Head and neck cancer; Mucositis; Quality of life; Radiotherapy; Xerostomia

Indexed keywords

ANTIINFECTIVE AGENT; BACITRACIN; BACITRACIN PLUS CLOTRIMAZOLE PLUS GENTAMICIN; CLOTRIMAZOLE; GENTAMICIN; PLACEBO; UNCLASSIFIED DRUG;

ADULT; AGED; ANTIMICROBIAL ACTIVITY; APPETITE DISORDER; ARTICLE; CANCER PAIN; CANCER RADIOTHERAPY; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DENTAL CARIES; DIARRHEA; DOUBLE BLIND PROCEDURE; DYSPHAGIA; DYSPNEA; ESOPHAGITIS; FACE PAIN; FATIGUE; FEMALE; HEAD AND NECK CANCER; HUMAN; LOZENGE; MAJOR CLINICAL STUDY; MALE; MUCOSA INFLAMMATION; MULTICENTER STUDY; NAUSEA; PAIN; PRIORITY JOURNAL; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL; RISK BENEFIT ANALYSIS; SCORING SYSTEM; SIDE EFFECT; TOOTH PAIN; XEROSTOMIA;

ADMINISTRATION, ORAL; ANTI-INFECTIVE AGENTS; BACITRACIN; CARCINOMA, SQUAMOUS CELL; CLOTRIMAZOLE; DOUBLE-BLIND METHOD; DRUG COMBINATIONS; FEMALE; GENTAMICINS; HEAD AND NECK NEOPLASMS; HUMANS; MALE; MIDDLE AGED; QUALITY OF LIFE; QUESTIONNAIRES; RADIOTHERAPY; STOMATITIS; XEROSTOMIA;

EID: 17844393345     PISSN: 10433074     EISSN: None     Source Type: Journal    
DOI: 10.1002/hed.20162     Document Type: Article

References (51)

1. Trotti A. Toxicity in head and neck cancer: a review of trends and issues. Int J Radiat Oncol Biol Phys 2000;47:1-12.
2. Vissink A, Burlage FR, Spijkervet FK, Jansma J, Coppes RP. Prevention and treatment of the consequences of head and neck radiotherapy. Crit Rev Oral Biol Med 2003;14:213-225.
3. Vissink A, Jansma J, Spijkervet FK, Burlage FR, Coppes RP. Oral sequelae of head and neck radiotherapy. Crit Rev Oral Biol Med 2003;14:199-212.
4. Spijkervet FK, van Saene HK, van Saene JJ, Panders AK, Vermey A, Mehta DM. Mucositis prevention by selective elimination of oral flora in irradiated head and neck cancer patients. J Oral Pathol Med 1990;19:486-489.
5. Spijkervet FK, Van Saene HK, Van Saene JJ, et al. Effect of selective elimination of the oral flora on mucositis in irradiated head and neck cancer patients. J Surg Oncol 1991;46:167-173.
6. Symonds RP, McIlroy P, Khorrami J, et al. The reduction of radiation mucositis by selective decontamination antibiotic pastilles: a placebo-controlled double-blind trial. Br J Cancer 1996;74:312-317.
7. Foote RL, Loprinzi CL, Frank AR, et al. Randomized trial of a chlorhexidine mouthwash for alleviation of radiation-induced mucositis. J Clin Oncol 1994;12:2630-2633.
8. El-Sayed S, Nabid A, Shelley W, et al. Prophylaxis of radiation-associated mucositis in conventionally treated patients with head and neck cancer: a double-blind, phase III, randomized, controlled trial evaluating the clinical efficacy of an antimicrobial lozenge using a validated mucositis scoring system. J Clin Oncol 2002;20:3956-3963.
9. Sutherland SE, Browman GP. Prophylaxis of oral mucositis in irradiated head-and-neck cancer patients: a proposed classification scheme of interventions and meta-analysis of randomized controlled trials. Int J Radiat Oncol Biol Phys 2001;49:917-930.
10. El-Sayed S, Epstein J, Minish E, Burns P, Hay J, Laukkanen E. A pilot study evaluating the safety and microbiologic efficacy of an economically viable antimicrobial lozenge in patients with head and neck cancer receiving radiation therapy. Head Neck 2002;24:6-15.
11. Talmi YP. Quality of life issues in cancer of the oral cavity. J Laryngol Otol 2002;116:785-790.
12. Sonis ST, Eilers JP, Epstein JB, et al. Validation of a new scoring system for the assessment of clinical trial research of oral mucositis induced by radiation or chemotherapy. Mucositis Study Group. Cancer 1999;85:2103-2113.
13. Epstein JB, Emerton S, Kolbinson DA, et al. Quality of life and oral function following radiotherapy for head and neck cancer. Head Neck 1999;21:1-11.
14. Epstein JB, Robertson M, Emerton S, Phillips N, Stevenson-Moore P. Quality of life and oral function in patients treated with radiation therapy for head and neck cancer. Head Neck 2001;23:389-398.
15. Epstein JB, Phillips N, Parry J, Epstein MS, Nevill T, Stevenson-Moore P. Quality of life, taste, olfactory and oral function following high-dose chemotherapy and allogeneic hematopoietic cell transplantation. Bone Marrow Transplant 2002;30:785-792.
16. Hassan SJ, Weymuller EA Jr. Assessment of quality of life in head and neck cancer patients. Head Neck 1993;15:485-496.
17. D'Antonio LL, Zimmerman GJ, Cella DF, Long SA. Quality of life and functional status measures in patients with head and neck cancer. Arch Otolaryngol Head Neck Surg 1996;122:482-487.
18. Bjordal K, Kaasa S, Mastekaasa A. Quality of life in patients treated for head and neck cancer: a follow-up study 7 to 11 years after radiotherapy. Int J Radiat Oncol Biol Phys 1994;28:847-856.
19. Browman GP, Levine MN, Hodson DI, et al. The Head and Neck Radiotherapy Questionnaire: a morbidity/quality-of-life instrument for clinical trials of radiation therapy in locally advanced head and neck cancer. J Clin Oncol 1993;11:863-872.
20. Osoba D, Slamon DJ, Burchmore M, Murphy M. Effects on quality of life of combined trastuzumab and chemotherapy in women with metastatic breast cancer. J Clin Oncol 2002;20:3106-3113.
21. Osoba D, Rodrigues G, Myles J, Zee B, Pater J. Interpreting the significance of changes in health-related quality-of-life scores. J Clin Oncol 1998;16:139-144.
22. Bjordal K, Ahlner-Elmqvist M, Tollesson E, et al. Development of a European Organization for Research and Treatment of Cancer (EORTC) questionnaire module to be used in quality of life assessments in head and neck cancer patients. EORTC Quality of Life Study Group. Acta Oncol 1994;33:879-885.
23. Bjordal K, Hammerlid E, Ahlner-Elmqvist M, et al. Quality of life in head and neck cancer patients: validation of the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-H&N35. J Clin Oncol 1999;17:1008-1019.
24. Rogers SN, Lowe D, Brown JS, Vaughan ED. A comparison between the University of Washington Head and Neck Disease-Specific measure and the Medical Short Form 36, EORTC QOQ-C33 and EORTC Head and Neck 35. Oral Oncol 1998;34:361-372.
25. Rogers SN, Fisher SE, Woolgar JA. A review of quality of life assessment in oral cancer. Int J Oral Maxillofac Surg 1999;28:99-117.
26. List MA, D'Antonio LL, Cella DF, et al. The Performance Status Scale for Head and Neck Cancer Patients and the Functional Assessment of Cancer Therapy-Head and Neck Scale. A study of utility and validity. Cancer 1996;77:2294-2301.
27. List MA, Siston A, Haraf D, et al. Quality of life and performance in advanced head and neck cancer patients on concomitant chemoradiotherapy: a prospective examination. J Clin Oncol 1999;17:1020-1028.
28. List MA, Mumby P, Haraf D, et al. Performance and quality of life outcome in patients completing concomitant chemoradiotherapy protocols for head and neck cancer. Qual Life Res 1997;6:274-284.
29. List MA, Stracks J. Evaluation of quality of life in patients definitively treated for squamous carcinoma of the head and neck. Curr Opin Oncol 2000;12:215-220.
30. Ringash J, Bezjak A. A structured review of quality of life instruments for head and neck cancer patients. Head Neck. 2001;23:201-213.
31. Bansal M, Mohanti BK, Shah N, Chaudhry R, Bahadur S, Shukla NK. Radiation-related morbidities and their impact on quality of life in head and neck cancer patients receiving radical radiotherapy. Qual Life Res 2004;13:481-488.
32. Wijers OB, Levendag PC, Harms ER, et al. Mucositis reduction by selective elimination of oral flora in irradiated cancers of the head and neck: a placebo-controlled double-blind randomized study. Int J Radiat Oncol Biol Phys 2001;50:343-352.
33. Fisher J, Scott C, Scarantino CW, et al. Phase III quality-of-life study results: impact on patients' quality of life to reducing xerostomia after radiotherapy for head-and-neck cancer-RTOG 97-09. Int J Radiat Oncol Biol Phys 2003;56:832-836.
34. Warde P, O'Sullivan B, Aslanidis J, et al. A Phase III placebo-controlled trial of oral pilocarpine in patients undergoing radiotherapy for head-and-neck cancer. Int J Radiat Oncol Biol Phys 2002;54:9-13.
35. Horiot JC, Lipinski F, Schraub S, et al. Post-radiation severe xerostomia relieved by pilocarpine: a prospective French cooperative study. Radiother Oncol 2000;55:233-239.
36. Ackerstaff AH, Tan IB, Rasch CR, et al. Quality-of-life assessment after supradose selective intra-arterial cisplatin and concomitant radiation (RADPLAT) for inoperable stage IV head and neck squamous cell carcinoma. Arch Otolaryngol Head Neck Surg 2002;128:1185-1190.
37. Nguyen NP, Sallah S, Karlsson U, Antoine JE. Combined chemotherapy and radiation therapy for head and neck malignancies: quality of life issues. Cancer 2002;94:1131-1141.
38. Huguenin PU, Taussky D, Moe K, et al. Quality of life in patients cured from a carcinoma of the head and neck by radiotherapy: the importance of the target volume. Int J Radiat Oncol Biol Phys 1999;45:47-52.
39. Guchelaar HJ, Vermes A, Meerwaldt JH. Radiation-induced xerostomia: pathophysiology, clinical course and supportive treatment. Support Care Cancer 1997;5:281-288.
40. Allal AS, Dulguerov P, Bieri S, Lehmann W, Kurtz JM. Assessment of quality of life in patients treated with accelerated radiotherapy for laryngeal and hypopharyngeal carcinomas. Head Neck 2000;22:288-293.
41. Eisbruch A, Dawson LA, Kim HM, et al. Conformal and intensity modulated irradiation of head and neck cancer: the potential for improved target irradiation, salivary gland function, and quality of life. Acta Oto-Rhino-Laryngol Belg 1999;53:271-275.
42. Henson BS, Inglehart MR, Eisbruch A, Ship JA. Preserved salivary output and xerostomia-related quality of life in head and neck cancer patients receiving parotid-sparing radiotherapy. Oral Oncol 2001;37:84-93.
43. Lin A, Kim HM, Terrell JE, Dawson LA, Ship JA, Eisbruch A. Quality of life after parotid-sparing IMRT for head-and-neck cancer: a prospective longitudinal study. Int J Radiat Oncol Biol Phys 2003;57:61-70.
44. Parliament MB, Scrimger RA, Anderson SG, et al. Preservation of oral health-related quality of life and salivary flow rates after inverse-planned intensity-modulated radiotherapy (IMRT) for head-and-neck cancer. Int J Radiat Oncol Biol Phys 2004;58:663-673.
45. Chao KS, Deasy JO, Markman J, et al. A prospective study of salivary function sparing in patients with head-and-neck cancers receiving intensity-modulated or three-dimensional radiation therapy: initial results. Int J Radiat Oncol Biol Phys 2001;49:907-916.
46. Cengiz M, Ozyar E, Ozturk D, Akyol F, Atahan IL, Hayran M. Sucralfate in the prevention of radiation-induced oral mucositis. J Clin Gastroenterol 1999;28:40-43.
47. Pico JL, Avila-Garavito A. Naccache P. Mucositis: its occurrence, consequences, and treatment in the oncology setting. Oncologist 1998;3(6):446-451.
48. Trotti A, Bellm LA, Epstein JB, et al. Mucositis incidence, severity and associated outcomes in patients with head and neck cancer receiving radiotherapy with or without chemotherapy: a systematic literature review. Radiother Oncol 2003;66:253-262.
49. Mabro M, Faivre S, Raymond E. A risk-benefit assessment of amifostine in cytoprotection. Drug Saf 1999;21:367-387.
50. Airoldi M, Cortesina G, Giordano C, et al. Postoperative adjuvant chemoradiotherapy in older patients with head and neck cancer. Arch Otolaryngol Head Neck Surg 2004;130:161-166.
51. Yokes EE, Kies MS, Haraf DJ, et al. Concomitant chemoradiotherapy as primary therapy for locoregionally advanced head and neck cancer. J Clin Oncol 2000;18:1652-1661.